why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat

Course: Evolving Treatment Approaches for Relapsed and Refractory Multiple Myeloma: Integrating the Latest Evidence Into the Care of Patients in Rural and Underserved Communities

CME Credits: 0.00

Released: 2025-09-19

Over the past two decades, treatment advancements in multiple myeloma—including proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and autologous stem cell transplantation—have significantly improved patient outcomes. However, none are curative, creating the need for subsequent therapy. Individuals in rural and underserved communities face barriers to advanced oncology care, resulting in delayed diagnosis, lower quality management, and higher mortality. This on-demand CME/CE activity will review the latest clinical evidence and guideline-based recommendations for the treatment of relapsed/refractory multiple myeloma. Expert faculty will discuss emerging efficacy and safety data for novel therapies, strategies to optimize treatment selection and sequencing, and approaches to expand access to care in rural and underserved settings. This enduring activity is a recorded session from Oncology Congress Spring 2025 that took place on June 14, 2025.


Upon completion of this activity, participants should be better able to:


View Full Course